Journal article · 2019 · Open access

A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy

Christopher Anthony Duplessis, Michael G. Stockelman, Theron Hamilton, Greg Merril, Michael Brownstein, Kimberly A. Bishop‐Lilly, Robert Turner Schooley, Matthew Henry, Bri’Anna Horne, Brittany M. Sisson, Javier Quiñónes, Saima Aslam and 3 more

Journal of Intensive and Critical Care, 5(2) · Published 1 January 2019

Read the free full textCite this paper

In brief

“A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy” is a 2019 journal article by Christopher Anthony Duplessis and 14 co-authors, published in Journal of Intensive and Critical Care. OpenAlex counts 27 citations as of 15 November 2026, which puts it in the top 7% of works published in 2019 by citations. It is open access: the full text is free to read at Journal of Intensive and Critical Care.

Citations
27
Most cited in
2021 (7)
Field-weighted impact
1.71
Authors
15

Abstract

The advent and increasing prevalence of antimicrobial resistance commensurate with the absence of novel antibiotics on the horizon raises the spectre of untreatable infections. We must now grapple with infections stemming from extensively multi- and pan-drug resistant bacterial strains. Potential non-antibiotic options to treat Multi-Drug Resistant (MDR) infections include bacteriophages and there has been much fervour in resurrecting research into its clinical use. Although not subjected to the contemporary rigorous scientific standards for clinical trials, there appears to be an abundance of data purporting safety of bacteriophage therapy regardless of administration route. The US Navy and Adaptive Phage Therapeutics have taken a precision approach to development of bacteriophage therapy. Herein, as opposed to fixed phage cocktails, we exploit the quintessential example of personalized medicine by acquiring the patient’s infecting isolate and identifying a phage cocktail proven to lyse the bacteria. As we prepare to execute our FDA regulated clinical phase II bacteriophage therapeutic trials in the ensuing year(s), we have engaged in numerous compassionate use eIND cases to provide potentially life-saving bacteriophage treatment to patients either failing conventional antibiotic therapy due to MDR resistance, or stemming from an inability to secure definitive source control. In all eIND cases, “personalized” bacteriophage cocktails were selected which “targeted” the infecting organism. This case series reports upon 13 emergencies investigational new drug (eIND) cases whereby patients failing antibiotic therapy safely received bacteriophage mixtures (cocktails) without identifying any bacteriophagemediated adverse effects. Adjudicated microbiologic eradication of the targeted bacterial isolate was achieved in 11 cases, while 6 cases were clinically adjudicated to have achieved therapeutic efficacy defined as clinical resolution. The balance of non-resolved cases was secondary to curtailed therapy (patient expiring), noninfectious mediated organ failure, or relapse of infection from biofilm-mediated infections.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Duplessis, C. A., Stockelman, M. G., Hamilton, T., Merril, G., Brownstein, M., Bishop‐Lilly, K. A., Schooley, R. T., Henry, M., Horne, B., Sisson, B. M., Quiñónes, J., Aslam, S., Lavergne, S. N., Nir‐Paz, R., & Biswas, B. (2019). A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy. Journal of Intensive and Critical Care, 5(2). https://criticalcare.imedpub.com/a-case-series-of-emergency-investigational-new-drug-applications-for-bacteriophages-treating-recalcitrant-multidrug-resistant-bact.pdf

MLA 9

Duplessis, Christopher Anthony, et al. “A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy.” Journal of Intensive and Critical Care, vol. 5, no. 2, 2019. https://criticalcare.imedpub.com/a-case-series-of-emergency-investigational-new-drug-applications-for-bacteriophages-treating-recalcitrant-multidrug-resistant-bact.pdf.

Chicago

Duplessis, Christopher Anthony, Michael G. Stockelman, Theron Hamilton, Greg Merril, Michael Brownstein, Kimberly A. Bishop‐Lilly, Robert Turner Schooley, et al. 2019. “A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy.” Journal of Intensive and Critical Care 5 (2). https://criticalcare.imedpub.com/a-case-series-of-emergency-investigational-new-drug-applications-for-bacteriophages-treating-recalcitrant-multidrug-resistant-bact.pdf.

Harvard

Duplessis, C. A. et al. (2019) ‘A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy’, Journal of Intensive and Critical Care, 5(2). Available at: https://criticalcare.imedpub.com/a-case-series-of-emergency-investigational-new-drug-applications-for-bacteriophages-treating-recalcitrant-multidrug-resistant-bact.pdf.

IEEE

C. A. Duplessis et al., “A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy,” Journal of Intensive and Critical Care, vol. 5, no. 2, 2019.

BibTeX

@article{duplessis2019case,
  title     = {{A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy}},
  author    = {Duplessis, Christopher Anthony and Stockelman, Michael G. and Hamilton, Theron and Merril, Greg and Brownstein, Michael and Bishop‐Lilly, Kimberly A. and Schooley, Robert Turner and Henry, Matthew and Horne, Bri’Anna and Sisson, Brittany M. and Quiñónes, Javier and Aslam, Saima and Lavergne, Sidonie N. and Nir‐Paz, Ran and Biswas, Biswajit},
  journal   = {Journal of Intensive and Critical Care},
  year      = {2019},
  volume    = {5},
  number    = {2},
  url       = {https://criticalcare.imedpub.com/a-case-series-of-emergency-investigational-new-drug-applications-for-bacteriophages-treating-recalcitrant-multidrug-resistant-bact.pdf}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202022
202177
202277
202366
202433
202522

Its field-weighted citation impact is 1.71: it has been cited 1.71 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Immunology and Microbiology › Virology › Bacteriophages and microbial interactions

  • phage therapy
  • multidrug-resistant bacteria
  • compassionate use
  • phage safety
  • antimicrobial resistance
  • biofilm-associated infections
  • microbiologic eradication

Work with this paper

Most-cited papers in Immunology and Microbiology

All highly cited Immunology and Microbiology papers

Questions about this paper

How do I cite this paper in APA style?

Duplessis, C. A., Stockelman, M. G., Hamilton, T., Merril, G., Brownstein, M., Bishop‐Lilly, K. A., Schooley, R. T., Henry, M., Horne, B., Sisson, B. M., Quiñónes, J., Aslam, S., Lavergne, S. N., Nir‐Paz, R., & Biswas, B. (2019). A Case Series of Emergency Investigational New Drug Applications for Bacteriophages Treating Recalcitrant Multi-drug Resistant Bacterial Infections: Confirmed Safety and a Signal of Efficacy. Journal of Intensive and Critical Care, 5(2). https://criticalcare.imedpub.com/a-case-series-of-emergency-investigational-new-drug-applications-for-bacteriophages-treating-recalcitrant-multidrug-resistant-bact.pdf

How many times has this paper been cited?

27 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access: read the free full text at Journal of Intensive and Critical Care.

Who wrote this paper?

Christopher Anthony Duplessis, Michael G. Stockelman, Theron Hamilton, Greg Merril, Michael Brownstein, Kimberly A. Bishop‐Lilly, Robert Turner Schooley, Matthew Henry, Bri’Anna Horne, Brittany M. Sisson, Javier Quiñónes, Saima Aslam and 3 more.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.